FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 342:1686-1692 June 8, 2000 Number 23 Next

	Full Text PDF Editorial by Kessler, D. A. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Chinese-herb nephropathy is a progressive form of renal fibrosis that develops in some patients who take weight-reducing pills containing Chinese herbs. Because of a manufacturing error, one of the herbs in these pills (Stephania tetrandra) was inadvertently replaced by Aristolochia fangchi, which is nephrotoxic and carcinogenic.

Methods The diagnosis of a neoplastic lesion in the native urinary tract of a renal-transplant recipient who had Chinese-herb nephropathy prompted us to propose regular cystoscopic examinations and the prophylactic removal of the native kidneys and ureters in all our patients with end-stage Chinese-herb nephropathy who were being treated with either transplantation or dialysis. Surgical specimens were examined histologically and analyzed for the presence of DNA adducts formed by aristolochic acid. All prescriptions written for weight-reducing compounds during the period of exposure (1990 to 1992) in these patients were obtained, and the cumulative doses were calculated.

Results Among 39 patients who agreed to undergo prophylactic surgery, there were 18 cases of urothelial carcinoma (prevalence, 46 percent; 95 percent confidence interval, 29 to 62 percent): 17 cases of carcinoma of the ureter, renal pelvis, or both and 1 papillary bladder tumor. Nineteen of the remaining patients had mild-to-moderate urothelial dysplasia, and two had normal urothelium. All tissue samples analyzed contained aristolochic acid–related DNA adducts. The cumulative dose of aristolochia was a significant risk factor for urothelial carcinoma, with total doses of more than 200 g associated with a higher risk of uro-thelial carcinoma.

Conclusions The prevalence of urothelial carcinoma among patients with end-stage Chinese-herb nephropathy (caused by aristolochia species) is high.

Source Information

From the Departments of Nephrology (J.L.N., M.-C.M.M., L.D., D.A., P.V., J.-L.V.) and Pathology (M.P., M.F.D.), Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; and the Division of Molecular Toxicology, German Cancer Research Center, Heidelberg, Germany (H.H.S., V.M.A., C.A.B.).

Address reprint requests to Dr. Nortier at the Nephrology Department, Hôpital Erasme, Université Libre de Bruxelles, Route de Lennik, 808, B-1070 Brussels, Belgium, or at jnortier{at}ulb.ac.be.

Full Text of this Article

Related Letters:

Chinese Herbs and Urothelial Carcinoma
Shum S., Lu W., Lu W., Li Y. M., Nortier J. L., Vanherweghem J.-L., Schmeiser H. H.
Extract | Full Text  
N Engl J Med 2000; 343:1268-1270, Oct 26, 2000. Correspondence

This article has been cited by other articles:

• Tachjian, A., Maria, V., Jahangir, A. (2010). Use of Herbal Products and Potential Interactions in Patients With Cardiovascular Diseases. J Am Coll Cardiol 55: 515-525 [Abstract] [Full Text]  
• Lai, M.-N., Wang, S.-M., Chen, P.-C., Chen, Y.-Y., Wang, J.-D. (2010). Population-Based Case-Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk. JNCI J Natl Cancer Inst 102: 179-186 [Abstract] [Full Text]  
• Attaluri, S., Bonala, R. R., Yang, I.-Y., Lukin, M. A., Wen, Y., Grollman, A. P., Moriya, M., Iden, C. R., Johnson, F. (2010). DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res 38: 339-352 [Abstract] [Full Text]  
• Stemmer, K., Ellinger-Ziegelbauer, H., Ahr, H.-J., Dietrich, D. R. (2009). Molecular Characterization of Preneoplastic Lesions Provides Insight on the Development of Renal Tumors. Am. J. Pathol. 175: 1686-1698 [Abstract] [Full Text]  
• Xue, X., Xiao, Y., Zhu, H., Wang, H., Liu, Y., Xie, T., Ren, J. (2008). Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol Dial Transplant 23: 3074-3081 [Abstract] [Full Text]  
• van Breemen, R. B, Fong, H. H., Farnsworth, N. R (2008). Ensuring the safety of botanical dietary supplements. Am. J. Clin. Nutr. 87: 509S-513S [Abstract] [Full Text]  
• Lin, Y.-L., Chen, H.-H., Chen, T.-W. (2008). Asymptomatic renal failure in a patient with bipolar disease without lithium therapy. NDT Plus 1: 45-48 [Full Text]  
• Shariat, S. F., Lamb, D. J., Roehrborn, C. G., Slawin, K. M. (2008). Potentially Harmful Effect of a Testosterone Dietary Supplement on Prostate Cancer Growth and Metastasis. Arch Intern Med 168: 235-236 [Full Text]  
• Shariat, S. F., Lamb, D. J., Iyengar, R. G., Roehrborn, C. G., Slawin, K. M. (2008). Herbal/Hormonal Dietary Supplement Possibly Associated with Prostate Cancer Progression. Clin. Cancer Res. 14: 607-611 [Abstract] [Full Text]  
• de Jonge, H., Vanrenterghem, Y. (2008). Aristolochic acid: the common culprit of Chinese herbs nephropathy and Balkan endemic nephropathy. Nephrol Dial Transplant 23: 39-41 [Full Text]  
• Prevost, R. R. (2007). Pharmacy Review: Lifestyle Management of Obesity: Considerations for Pharmacists. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 451-453 [Abstract]  
• Arlt, V. M., Stiborova, M., vom Brocke, J., Simoes, M. L., Lord, G. M., Nortier, J. L., Hollstein, M., Phillips, D. H., Schmeiser, H. H. (2007). Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28: 2253-2261 [Abstract] [Full Text]  
• Grollman, A. P., Jelakovic, B. (2007). Role of Environmental Toxins in Endemic (Balkan) Nephropathy. J. Am. Soc. Nephrol. 18: 2817-2823 [Abstract] [Full Text]  
• Shibutani, S., Dong, H., Suzuki, N., Ueda, S., Miller, F., Grollman, A. P. (2007). Selective Toxicity of Aristolochic Acids I and II. Drug Metab. Dispos. 35: 1217-1222 [Abstract] [Full Text]  
• Gabardi, S., Munz, K., Ulbricht, C. (2007). A Review of Dietary Supplement-Induced Renal Dysfunction. CJASN 2: 757-765 [Abstract] [Full Text]  
• Nortier, J. L., Vanherweghem, J.-L. (2007). For patients taking herbal therapy--lessons from aristolochic acid nephropathy. Nephrol Dial Transplant 22: 1512-1517 [Full Text]  
• Arlt, V. M., Frei, E., Schmeiser, H. H. (2007). ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006. Mutagenesis 22: 83-88 [Abstract] [Full Text]  
• Brocke, J. v., Schmeiser, H. H., Reinbold, M., Hollstein, M. (2006). MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27: 2141-2147 [Abstract] [Full Text]  
• Dong, H., Suzuki, N., Torres, M. C., Bonala, R. R., Johnson, F., Grollman, A. P., Shibutani, S. (2006). QUANTITATIVE DETERMINATION OF ARISTOLOCHIC ACID-DERIVED DNA ADDUCTS IN RATS USING 32P-POSTLABELING/POLYACRYLAMIDE GEL ELECTROPHORESIS ANALYSIS. Drug Metab. Dispos. 34: 1122-1127 [Abstract] [Full Text]  
• Tascilar, M., de Jong, F. A., Verweij, J., Mathijssen, R. H. J. (2006). Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence. The Oncologist 11: 732-741 [Abstract] [Full Text]  
• Liang, F.-X., Bosland, M. C., Huang, H., Romih, R., Baptiste, S., Deng, F.-M., Wu, X.-R., Shapiro, E., Sun, T.-T. (2005). Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement. JCB 171: 835-844 [Abstract] [Full Text]  
• Lebeau, C., Debelle, F. D., Arlt, V. M., Pozdzik, A., De Prez, E. G., Phillips, D. H., Deschodt-Lanckman, M. M., Vanherweghem, J.-L., Nortier, J. L. (2005). Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant 20: 2321-2332 [Abstract] [Full Text]  
• Smolinske, S. C. (2005). Herbal Product Contamination and Toxicity. Journal of Pharmacy Practice 18: 188-208 [Abstract]  
• Wu, Y., Liu, Z., Hu, W., Li, L. (2005). Mast cell infiltration associated with tubulointerstitial fibrosis in chronic Aristolochic Acid Nephropathy. Hum Exp Toxicol 24: 41-47 [Abstract]  
• Cui, M., Liu, Z.-H., Qiu, Q., Li, H., Li, L.-S. (2005). Tumour induction in rats following exposure to short-term high dose aristolochic acid I. Mutagenesis 20: 45-49 [Abstract] [Full Text]  
• Wooltorton, E. (2004). Several Chinese herbal products may contain toxic aristolochic acid. CMAJ 171: 449-449 [Full Text]  
• Lo, S. H.-K., Mo, K.-L., Wong, K.-S., Poon, S.-P., Chan, C.-K., Lai, C.-K., Chan, A. (2004). Aristolochic acid nephropathy complicating a patient with focal segmental glomerulosclerosis. Nephrol Dial Transplant 19: 1913-1915 [Full Text]  
• Tanne, J. H. (2004). US consumer group names "dirty dozen" dietary supplements. BMJ 328: 975-975 [Full Text]  
• Liu, Z., Hergenhahn, M., Schmeiser, H. H., Wogan, G. N., Hong, A., Hollstein, M. (2004). Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. USA 101: 2963-2968 [Abstract] [Full Text]  
• Navo, M. A., Phan, J., Vaughan, C., Palmer, J. L., Michaud, L., Jones, K. L., Bodurka, D. C., Basen-Engquist, K., Hortobagyi, G. N., Kavanagh, J. J., Smith, J. A. (2004). An Assessment of the Utilization of Complementary and Alternative Medication in Women With Gynecologic or Breast Malignancies. JCO 22: 671-677 [Abstract] [Full Text]  
• Okada, H., Watanabe, Y., Inoue, T., Kobayashi, T., Kanno, Y., Shiota, G., Nakamura, T., Sugaya, T., Fukamizu, A., Suzuki, H. (2003). Transgene-derived hepatocyte growth factor attenuates reactive renal fibrosis in aristolochic acid nephrotoxicity. Nephrol Dial Transplant 18: 2515-2523 [Abstract] [Full Text]  
• Gold, L. S., Slone, T. H. (2003). Aristolochic Acid, an Herbal Carcinogen, Sold on the Web after FDA Alert. NEJM 349: 1576-1577 [Full Text]  
• Stiborova, M., Frei, E., Sopko, B., Sopkova, K., Markova, V., Lankova, M., Kumstyrova, T., Wiessler, M., Schmeiser, H. H. (2003). Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24: 1695-1703 [Abstract] [Full Text]  
• Larimore, W. L, O'Mathuna, D. P (2003). Quality Assessment Programs for Dietary Supplements. The Annals of Pharmacotherapy 37: 893-898 [Abstract] [Full Text]  
• Halsted, C. H (2003). Dietary supplements and functional foods: 2 sides of a coin?. Am. J. Clin. Nutr. 77: 1001S-1007 [Abstract] [Full Text]  
• Wetzel, M. S., Kaptchuk, T. J., Haramati, A., Eisenberg, D. M. (2003). Complementary and Alternative Medical Therapies: Implications for Medical Education. ANN INTERN MED 138: 191-196 [Abstract] [Full Text]  
• Nortier, J. L., Schmeiser, H. H., Martinez, M.-C. M., Arlt, V. M., Vervaet, C., Garbar, C. H., Daelemans, P., Vanherweghem, J.-L. (2003). Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. Nephrol Dial Transplant 18: 426-428 [Full Text]  
• Kanaan, N., Cosyns, J.-P., Jadoul, M., Goffin, E. (2003). The importance of a histology-based diagnosis of interstitial nephropathy in two patients with renal insufficiency. Nephrol Dial Transplant 18: 440-442 [Full Text]  
• De Smet, P. A.G.M. (2002). Herbal Remedies. NEJM 347: 2046-2056 [Full Text]  
• Marcus, D. M., Grollman, A. P. (2002). Botanical Medicines -- The Need for New Regulations. NEJM 347: 2073-2076 [Full Text]  
• Mason, R G, Donaldson, D (2002). Lessons to be learned: a case study approach: Chinese herbal nephropathy and urothelial malignancy. The Journal of the Royal Society for the Promotion of Health 122: 266-267 [Abstract]  
• Siemiatycki, J. (2002). Commentary: Epidemiology on the side of the angels. Int J Epidemiol 31: 1027-1029 [Full Text]  
• Markman, M. (2002). Safety Issues in Using Complementary and Alternative Medicine. JCO 20: 39s-41 [Abstract] [Full Text]  
• Fong, H. H. S. (2002). Integration of Herbal Medicine Into Modern Medical Practices: Issues and Prospects. Integr Cancer Ther 1: 287-293 [Abstract]  
• Arlt, V. M., Stiborova, M., Schmeiser, H. H. (2002). Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17: 265-277 [Abstract] [Full Text]  
• Cohen, M. H., Eisenberg, D. M. (2002). Potential Physician Malpractice Liability Associated with Complementary and Integrative Medical Therapies. ANN INTERN MED 136: 596-603 [Abstract] [Full Text]  
• Stiborova, M., Frei, E., Sopko, B., Wiessler, M., Schmeiser, H. H. (2002). Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23: 617-625 [Abstract] [Full Text]  
• Metcalfe, K., Corns, C., Fahie-Wilson, M., Mackenzie, P. (2002). Chinese medicines for slimming still cause health problems. BMJ 324: 679-679 [Full Text]  
• Martinez, M.-C. M., Nortier, J., Vereerstraeten, P., Vanherweghem, J.-L. (2002). Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. Nephrol Dial Transplant 17: 408-412 [Abstract] [Full Text]  
• Cronin, A. J., Maidment, G., Cook, T., Kite, G. C., Simmonds, M. S. J., Pusey, C. D., Lord, G. M. (2002). Aristolochic acid as a causative factor in a case of Chinese herbal nephropathy. Nephrol Dial Transplant 17: 524-525 [Full Text]  
• Debelle, F. D., Nortier, J. L., De Prez, E. G., Garbar, C. H., Vienne, A. R., Salmon, I. J., Deschodt-Lanckman, M. M., Vanherweghem, J.-L. (2002). Aristolochic Acids Induce Chronic Renal Failure with Interstitial Fibrosis in Salt-Depleted Rats. J. Am. Soc. Nephrol. 13: 431-436 [Abstract] [Full Text]  
• de Boer, J. G. (2001). Protection by Dietary Compounds against Mutation in a Transgenic Rodent. J. Nutr. 131: 3082S-3086 [Abstract] [Full Text]  
• Goldman, P. (2001). Herbal Medicines Today and the Roots of Modern Pharmacology. ANN INTERN MED 135: 594-600 [Abstract] [Full Text]  
• Penson, R. T., Castro, C. M., Seiden, M. V., Chabner, B. A., Lynch, T. J. Jr. (2001). Complementary, Alternative, Integrative, or Unconventional Medicine?. The Oncologist 6: 463-473 [Abstract] [Full Text]  
• Markman, M. (2001). Interactions Between Academic Oncology and Alternative/Complementary/Integrative Medicine: Complex But Necessary. JCO 19: 52s-53 [Full Text]  
• Rajendran, P. R., Thompson, R. E., Reich, S. G. (2001). The use of alternative therapies by patients with Parkinson's disease. Neurology 57: 790-794 [Abstract] [Full Text]  
• Ang-Lee, M. K., Moss, J., Yuan, C.-S. (2001). Herbal Medicines and Perioperative Care. JAMA 286: 208-216 [Abstract] [Full Text]  
• Murtaza, M., Singh, M., Dimitrov, V., Soni, A. (2001). Awareness of CAM Among Residents: A Long Way to Go. Arch Intern Med 161: 1679-1680 [Full Text]  
• Camus, Ph., Foucher, P., Bonniaud, Ph., Ask, K. (2001). Drug-induced infiltrative lung disease. Eur Respir J 18: 93S-100s [Abstract] [Full Text]  
• Liepa, G. (2001). Editorial: Cardioprotective Effects of {omega}-3 Fatty Acids: A Critical Review That Should Be Read by a Wide Range of Health Professionals. Nutr Clin Pract 16: 5-5  
• Sardesai, V. M., Myers, T. (2001). Clinincal Observations: Nutrient Supplements in Clinical Care. Nutr Clin Pract 16: 35-45 [Abstract]  
• Arlt, V. M., Schmeiser, H. H., Pfeifer, G. P. (2001). Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22: 133-140 [Abstract] [Full Text]  
• Shum, S., Lu, W., Lu, W., Li, Y. M., Nortier, J. L., Vanherweghem, J.-L., Schmeiser, H. H. (2000). Chinese Herbs and Urothelial Carcinoma. NEJM 343: 1268-1270 [Full Text]  
• Kessler, D. A. (2000). Cancer and Herbs. NEJM 342: 1742-1743 [Full Text]